Prescription medication affordability is a significant issue within the United States and has been associated with medication nonadherence and negative health outcomes [1-4]. These effects are compounded in vulnerable populations, including ethnic minority groups and uninsured individuals [1]. In 2022, entrepreneur Mark Cuban launched the Mark Cuban Cost Plus Drug Company (CostPlus)—a public benefit corporation with a vertically integrated supply chain—to address rising pharmaceutical costs [2,5]. CostPlus offers medications for a 15% markup and a US $5 pharmacy fee, allowing for significant cost savings [5]. Studies have found that pharmacy coupon websites can lead to significant savings for patients within dermatology, with GoodRx providing some of the highest rates of saving [6]. However, while GoodRx is often used, medication costs can vary significantly depending on the pharmacy. CostPlus offers the benefit of obtaining medications conveniently through a mail-in-one system, yet its potential benefits have not been described. We conducted an observational cost-analysis to assess cost savings between GoodRx and the novel CostPlus model.

The average medication cost, excluding shipping, was US $17 (SE US $3.22) through CostPlus and US $31.21 (SE US $6.42) through GoodRx (P<.001; Table 1). The average medication cost using the cheapest price available from GoodRx was US $21.34 (SE US $4.71), which remained significantly different from CostPlus (P=.03). When a US $2.60 shipping fee per medication was included, the average cost increased to US $19.60 (SE US $3.22), remaining significantly different from the average GoodRx cost (P<.001) [8]. When a US $5 shipping fee, which assumed that medications were shipped individually, was included on the CostPlus platform, the average cost rose to US $22 (SE US $3.22) but remained significantly different (P=.007) from the average GoodRx cost. On average, the retail cost of medications was US $147.23 (SE US $36.54). CostPlus resulted in average savings of US $130.23 (SE US $33.78; 81%), while GoodRx resulted in average savings of US $116.01 (SE US $30.73; 70%; Table 2). The two lowest-priced pharmacies with GoodRx were ShopRite and Acme in New York, Vons and Ralphs in Los Angeles, and Jewel-Osco and Meijer in Chicago (Multimedia Appendix 1).

We demonstrate that while use of either GoodRx or CostPlus allows for significant savings, CostPlus offers significantly higher rates of saving, even when isolating the lowest prices from GoodRx. Thus, CostPlus is a viable tool to reduce prescription medication burden within dermatology and especially among uninsured individuals or those with high-deductible health plans [5].

CostPlus may offer patients and clinicians more convenience in addition to greater cost savings. For example, the lowest prices in urban regions were derived from dozens of different pharmacies with variable prices. However, in rural areas, patients may have less pharmacy options, leading to higher costs. Furthermore, to obtain the greatest amount of cost savings for multiple prescriptions via GoodRx, patients may need to travel to various pharmacies. Transportation-related barriers can lead to delayed medical care, particularly in low-income and ethnic minority groups [9]. By shipping all prescriptions at once directly to patients, CostPlus may improve vulnerable patient populations’ access to care.

This study’s limitations include its observational nature, along with measurement of drug prices at a single time point. Additionally, a study by Patil et al [8] in 2023 found that 8% of dermatology patients are prescribed ≥5 medications, and our study did not fully assess the impact of ordering multiple medications at once. Further, our study did not assess prices from compounding pharmacies, which often offer discounted prices. Our study is also not generalizable, given that CostPlus is the first of its kind in the United States. Finally, certain common medications used in dermatology, including tretinoin and calcipotriene, are not available on CostPlus, which may limit its applicability.